<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104315">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02042261</url>
  </required_header>
  <id_info>
    <org_study_id>TB-TDM</org_study_id>
    <nct_id>NCT02042261</nct_id>
  </id_info>
  <brief_title>The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study</brief_title>
  <official_title>The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Schon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug resistant TB is increasing and in order to enchance the efficacy of the current drugs,
      individualized therapy using plasma drug concentrations and minimal inhibitory concentration
      (MIC) determination may be of importance. This concept is defined as therapeutic drug
      monitoring (TDM).

      In this pilot study our hypothesis is that the ratio between MIC and drug concentration data
      is correlated to the bacterial load measured as time to positive liquid culture (TTP).

      In two sites in Sweden, 25 patients with pulmonary tuberculosis will be recruited.
      MIC-determination of Mycobacterium tuberculosis will be performed in BACTEC 960 MGIT and
      drug concentration will be determined at 2, 4 and 12 weeks after treatment initiation using
      LC-MS/MS methodology. Sputum cultures will be obtained at 0, 2 days, 7 days, 2 weeks, 4
      weeks and 8 weeks and TTP will be measured in duplicate samples.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Time to positive Culture (TTP) in relation to rifampicin serum concentration and minimal inhibitory concentration (MIC)</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Active Tuberculosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed patients with culture verified tuberculosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age&gt;18 years, culture verified tuberculosis

        Exclusion Criteria:

        Other infectious diseases other than HIV or tuberculosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarina Niward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linköping University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarina Niward, MD</last_name>
    <phone>+1010100000</phone>
    <email>katarina.niward@lio.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Schön, MD PhD</last_name>
    <phone>+4648081567</phone>
    <email>tschon@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Infectious Diseases</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarina Niward, MD</last_name>
      <phone>+461010000000</phone>
      <email>katarina.niward@lio.se</email>
    </contact>
    <investigator>
      <last_name>Thomas Schön, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob Paues, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Infectious Diseases, TB-unit, Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17671</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Bruchfeldt, MD PhD</last_name>
      <phone>+4685858000</phone>
      <email>judith.bruchfeld@ki.se</email>
    </contact>
    <investigator>
      <last_name>Lina Davies-Forsman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Thomas Schon</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
